{"id":"NCT01214837","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","officialTitle":"A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-04","completion":"2012-05","firstPosted":"2010-10-05","resultsPosted":"2014-10-02","lastUpdate":"2018-10-09"},"enrollment":751,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]},{"type":"BIOLOGICAL","name":"Routine Vaccines","otherNames":[]}],"arms":[{"label":"MenACWY3","type":"EXPERIMENTAL"},{"label":"MenACWY4","type":"EXPERIMENTAL"},{"label":"Routine Vaccines","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.","primaryOutcome":{"measure":"Percentage of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) â‰¥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following a 4-dose Schedule of Men ACWY Vaccination.","timeFrame":"13 months of age","effectByArm":[{"arm":"MenACWY4","deltaMin":96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"55 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":40,"countries":["United States","Canada"]},"refs":{"pmids":["26479973"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":242},"commonTop":["Irritability","Somnolence","Injection site pain","Crying","Upper respiratory tract infection"]}}